

Same surface, different risk

*Evidence based medicine clearly shows
focusing on roughness is not the right approach
to understanding BIA-ALCL*

Dr. Oliver Boegershausen, POLYTECH

SCHEER Hearing, November 16, 2020

BIA-ALCL

What we (don't) know:

Very rare disease

No systematic data collection

Association with breast implants

(de Boer et al., 2018)

No known causation mechanism

Initial driving hypotheses on the cause of BIA-ALCL: bacterial contamination

**Rougher surfaces are larger,
with a higher the risk of BIA-ALCL**

(Loch-Wilkinson et al., 2017 PRS 140(4))

Justification:

- Most BIA-ALCL cases are with textured implants,
 - fewer cases with finer textured implants,
 - no cases (at the time) with smooth implants

Postulate:

- **Same surfaces should have the same incidence of BIA-ALCL**

Numbers used to justify the hypothesis

	Siltex	Biocell	Silimed PU
Worldwide cases of BIA-ALCL (FDA 20.08.2020 update)	~7%	~85%	?
Single-implant BIA-ALCL rate in Australia (Loch Wilkinson et al. 2019)	1:36,730	1:3,194	1:2,596

↓
1. Oversimplification
Rough textures must
be worse

↓
2. Oversimplification
PU must be a texture

Numbers that prove the hypothesis wrong

	Silimed PU	Microthane
Surface	Same polyurethane foam	
Confined geographical area	Australia	Western Europe
Period of sales	2008-2015*	
	* until Silimed lost its CE-mark and TGA-Approval due to particulate contamination	
Sales	46,728	46,569
Single-implant cases	18	1
Rate in Confined area	1:2,596	1:46,569
Rate worldwide	unknown	~1:100,000

↓
Significant statistical difference
(p-value: 0,0001)

Numbers that prove the hypothesis wrong

	(Bristol Myers Squibb) Surgitek PU
Patients in the U.S.A. until 1991 (FDA 1995)	~110,000
BIA-ALCL cases (FDA 20.08.2020 update)	Maximum 2 (6 cases attributed to 5 manufacturers)
Incidence	Maximum ~1:55,000

Hypothesis: *A tentative deduction about a phenomenon that can be verified*

→ If verified, it is provisionally confirmed

→ **If proven wrong, it must be abandoned or modified**

Publicly available data proves the surface roughness approach to BIA-ALCL is wrong.

However, focus is still on the classification of surfaces by roughness:

Barr et al., 2017; Atlan et al., 2018; Jones et al., 2018; ANSM (IEM Study) 2018, none of which globally agreed

EN ISO 14607:2018, merely descriptive, generally accepted



**None of these classifications relates in any way
to the risks of BIA-ALCL or to the implants' performance**



**A meaningful classification of surfaces
must have clinical relevance**

Starting over

What we need to do now?

- **Consider other (multifactorial) theories**
- **Use known data with an open mind**
- **Learn about relevant product differences**

What we need to do moving forward?

- **Collect more data, in a standardised form and promote registries**
- **Work on alternative classification**
- **Continue to inform patients and encourage awareness**

Consider other (multifactorial) theories

- Genetic predisposition: cancer incidence rates in Australia are
 - the highest for all cancers
 - and the second highest for non-Hodgkin lymphomas (after Lebanon)*

*International Agency for Research on Cancer, WHO



- Manufacturing differences among textures:
 - Salt loss (Allergan) as opposed to residue free techniques (POLYtxt, MESMO)
 - Production controls
- Leachables:
 - unconvincing, smooth and textured would have same incidence of BIA-ALCL

Use known data with an open mind

Looking at numbers again:


- Allergan Biocell and Silimed PU are *outliers*

Possible commonalities:

- Particle shedding (Allergan) / particle contamination (Silimed) (**Dutch RIVM study; Webb et al. 2017**)
- Double capsule (Allergan) / delamination (Silimed) leading to seroma (**Hamdi 2019; Hall-Findlay 2011; Spear et al. 2012; Efanov et al. 2017**)

Learn about relevant product differences

In topology (mathematics) a homeomorphism is the characteristic of two spaces whose surfaces are one the inverse function of the other, and thus correspond.







Sphere \leftrightarrow Cube
Torus \leftrightarrow Cup
Spere $\leftarrow X \rightarrow$ Torus



Texture

- Roughened silicone surface
- Created by plastically deforming the outermost non-vulcanised silicone layer of the shell, by several alternative techniques
- Bi-dimensional
- Smooth and textured surfaces are mutually homeomorphic



What does EN ISO 14607:2018, Annex H, say?


Reference to the average roughness (S_a) of surface, calculated as shown in picture

List of features typical of a solid surface.

While peaks and valleys project into a three-dimensional space, the surface itself is still two-dimensional.

In addition, sample material is the elastomer shell, with no mention of polyurethane

$$S_a = \frac{1}{A} \iint_A |Z(x,y)| dx dy$$





Polyurethane foam

Three-dimensional matrix

Not homeomorphic with silicone surfaces

Different

- Mechanically: not a rough surface
- Functionally: tissue grows *into* and not *onto* the surface
- Biologically: richly vascularised capsule with active immune cells



Collect more data, in a standardised form and promote registries

Data

- Uniformity and standardization within and among countries
- Collection of complete data sets:
 - type of diagnosis,
 - therapy and prognosis
 - current and prior implant/(s) and respective time *in situ*
 - implantation and replacement/explantation surgeries
 - recent and prior anamnesis
 - history/familiarity with other diseases and respective therapies
- Try to fill existing gaps in previously reported cases

Make breast implants registries compulsory, not only for BIA-ALCL

Work on alternative classification

Creation of standardized registries to collect *performance* data of different implant types, surfaces and brands

Possible criteria for classification:

- By rate of capsular contracture, most common complication in breast implant surgery
- By cumulative complications
- By reoperation rate

Continue to inform patients and spread awareness

Joint efforts of physicians, medical associations, manufacturers, distributors, authorities to:

- Provide information
 - to prospective patients
 - to patients who already received implants
- Promote participation in implant registries
- Promote regular controls, with or without symptoms
- Involve other physicians (e.g. ObGyns/Gyns, Family doctors)

Thank you

Bibliography

- Atlan M., “Breast implant surface texture impacts host tissue response”, *Journal of the Mechanical Behavior of Biomedical Materials*, Volume 88, December 2018, Pages 377-385.
- Barr *et al.*, “Functional biocompatibility testing of silicone breast implants and a novel classification system based on surface roughness”, *Journal of the Mechanical Behavior of Biomedical Materials*, 75 (2017) 75–81.
- de Boer *et al.* 2018, “Breast Implants and the Risk of Anaplastic Large-Cell Lymphoma in the Breast”, *JAMA Oncology* 4(3):335-341
- Efanov *et al.*, “Breast-implant texturing associated with delamination of capsular layers: a histological analysis of the double capsule phenomenon, *Ann. Chir. Plast. Esthet.*, 62 (2017), pp. 196-201.
- Food and Drug Administration (FDA), “Update: Study of the TDA released from polyurethane foam-covered breast implants”, 27.06.1995
- Food and Drug Administration (FDA), “FDA Updates Analysis of Medical Device Reports of Breast Implant Illness and Breast Implant-Associated Lymphoma”, 20.08.2020, <https://www.fda.gov/news-events/press-announcements/fda-updates-analysis-medical-device-reports-breast-implant-illness-and-breast-implant-associated>
- Hall-Findlay E., “Breast implants complication review: Double Capsules and late seromas”. *Plast Reconstr Surg.* 2011 Jan;127(1):56-66.
- Hamdi M., “Association Between Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL) Risk and Polyurethane Breast Implants: Clinical Evidence and European Perspective”, *Aesthetic Surgery Journal*, 2019 Jan 31;39(Supplement 1):S49-S54.
- International Agency for Research on Cancer (WHO), Estimated age-standardized incidence rates (World) in 2018, non-Hodgkin lymphoma, females, all ages, <https://gco.iarc.fr/today/online-analysis-map>
- Jones *et al.*, “The Functional Influence of Breast Implant Outer Shell Morphology on Bacterial Attachment and Growth”, *Plastic and Reconstructive Surgery*, 2018 October, 142(4):837-849 ANSM (IEM Study) 2018
- Loch Wilkinson *et al.*, “Breast Implant-Associated Anaplastic Large Cell Lymphoma in Australia and New Zealand: High-Surface-Area Textured Implants Are Associated with Increased Risk”, *Plastic Reconstructive Surgery*, 2017 Oct;140(4):645-654.
- Loch-Wilkinson *et al.* (2019), “Breast implant-associated anaplastic large cell lymphoma in Australia: a longitudinal study of implant and other related risk factors”. *Aesthet Surg J*
- Spear *et al.* (2012), “Late Seromas after Breast Implants. *Plastic and reconstructive surgery*”. 130(2):423—35.
- Venhuis *et al.*, “Risk analysis of particulate contamination on Silimed silicone-based breast implants”. RIVM Letter report 2015—0202. <https://www.rivm.nl/bibliotheek/rapporten/2015-0202.pdf>
- Webb *et al.*, “Textured Breast Implants: A Closer Look at Implant Debris Under the Microscope”, *Plast Surg (Oakv)*. 2017 Aug; 25(3): 179—183.